Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2018

# Manganese Catalyzed Reductive Amination of Aldehydes using Hydrogen as Reductant

Duo Wei,<sup>[a]</sup> Antoine Bruneau-Voisine,<sup>[a,b]</sup> Dmitry A. Valyaev,<sup>[b]</sup> Noël Lugan<sup>[b]</sup> and Jean-Baptiste Sortais<sup>\*[b,c]</sup>

[a] Duo Wei, Antoine Bruneau-Voisine Univ Rennes, CNRS, ISCR - UMR 6226, F-35042 Rennes, France

[b] Antoine Bruneau-Voisine, Dr. Dmitry A. Valyaev, Dr. Noël Lugan, Prof. Dr. Jean-Baptiste Sortais LCC-CNRS, Université de Toulouse, INPT, UPS 205 route de Narbonne, F-31077 Toulouse Cedex 4, France

Email : jean-baptiste.sortais@lcc-toulouse.fr

[c] Prof. Dr. Jean-Baptiste SortaisInstitut Universitaire de France1 rue Descartes, F-75231 Paris Cedex 05, France

#### Table of Contents

General information	3
General procedure for reductive amination reaction.	3
Specific procedure for reductive amination reaction on large scale (Table 2, entry 4)	4
Characterization of the products of the catalysis	5
Supplementary tables	
NMR Spectra of the products of reductive amination	23

# General information.

All reactions were carried out with oven-dried glassware using standard Schlenk techniques under an inert atmosphere of dry argon or in an argon-filled glove-box. Toluene, THF, diethyl ether, and dichloromethane were dried over a Braun MB-SPS-800 solvent purification system and degassed by thaw-freeze cycles. Ethanol (EtOH absolute anhydrous, Pure, Carlo Erba) was degassed and stored on molecular sieves 4 Å. Technical grade petroleum ether and ethyl acetate were used for chromatography column. Analytical TLC was performed on Merck  $60F_{254}$  silica gel plates (0.25 mm thickness). Column chromatography was performed on Acros Organics Ultrapure silica gel (mesh size 40-60  $\mu$ m, 60 Å). All reagents were obtained from commercial sources and liquid reagents were dried on 4 Å molecular sieves and degassed prior to use. Manganese pentacarbonyl bromide, min. 98%, was purchased from Strem Chemicals.

<sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F and <sup>31</sup>P NMR spectra were recorded in CDCl<sub>3</sub>, acetone-*d*<sub>6</sub>, or CD<sub>3</sub>OD, at 298 K, on Bruker, AVANCE 400 spectrometer at 400.1, 100.6, 376.5 and 162.2 MHz, respectively. <sup>1</sup>H and <sup>13</sup>C NMR spectra were calibrated against the residual solvent signal at the corresponding central peak (<sup>1</sup>H: CDCl<sub>3</sub> 7.26 ppm, acetone-*d*<sub>6</sub> 2.05 ppm, CD<sub>3</sub>OD 3.31 ppm; <sup>13</sup>C: CDCl<sub>3</sub> 77.16 ppm, acetone-*d*<sub>6</sub> 29.84 ppm, CD<sub>3</sub>OD 49.00 ppm). <sup>19</sup>F and <sup>31</sup>P NMR spectra calibrated against CFCl<sub>3</sub> and 85% H<sub>3</sub>PO<sub>4</sub> internal standard, respectively. Chemical shift ( $\delta$ ) and coupling constants (*J*) are given in ppm and in Hz, respectively. The peak patterns are indicated as follows: (s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; m, multiplet, and br. for broad).

Non-stirred Parr autoclaves (22 mL) were used for the hydrogenation.

GC analyses were performed with GC-2014 (Shimadzu) 2010 equipped with a 30 m capillary column (Supelco, SPBTM-20, fused silica capillary column,  $30 \text{ m} \times 0.25 \text{ mm} \times 0.25 \text{ mm}$  film thickness).

Low Resolution mass spectra were obtained on a QP2010 GC/MS apparatus from Shimadzu equipped with a 30 m capillary column (Supelco, SLBTM-5ms, fused silica capillary column, 30 M  $\times$  0.25 mm  $\times$  0.25 mm film thickness).

Specific rotations (in deg cm<sup>2</sup> g<sup>-1</sup>) were measured in a 1 dm thermostated quartz cell on a Jasco-P1010 polarimeter.

Manganese complexes 1-4 were synthesized according to the literature procedure.<sup>1</sup>

# General procedure for reductive amination reaction.

In an argon filled glove box, a 20 mL Schlenk tube was charged with aldehyde (0.5 mmol), amine (0.6 mmol) and anhydrous ethanol (2.0 mL). The reaction mixture was stirred at 100 °C (or at room temperature for aldehyde containing  $\alpha$ -protons) for 24 h. After cooling to room temperature, the mixture was transferred to a 20 mL autoclave followed by manganese complex **2** (5.0 mg, 2 mol%) and tBuOK (2.8 mg, 5 mol%). The autoclave was charged with H<sub>2</sub> (50 bar) and the mixture was stirred at indicated temperature in an oil bath (see Table 2, main article). After cooling to room temperature, the solution was diluted with ethyl acetate (2.0 mL) and filtered through a small pad of celite (2 cm in a Pasteur pipette). The celite was washed with ethyl acetate (2×2.0 mL). The filtrate was evaporated and the crude residue was purified by column chromatography (SiO<sub>2</sub>, mixture of petroleum ether/ethyl acetate as eluent).

### Specific procedure for reductive amination reaction on large scale (Table 2, entry 4).

A 50 mL Maximator autoclave ("Réacteur à ouverture rapide") was purged with N<sub>2</sub> and then charged with a solution of benzaldehyde (475  $\mu$ L, 4.3 mmol) and *p*-toluidine (500.0 mg, 4.6 mmol, 1.08 equiv.) in EtOH (10 mL). After stirring for 2 h at r.t., a solution of complex **2** (43 mg, 2 mol%) in EtOH (4 mL) and a solution of *t*BuOK (28 mg, 5 mol%) in EtOH (4 mL) were added under N<sub>2</sub> flow. The autoclave was charged with H<sub>2</sub> (50 bar) and the mixture was stirred at 100 °C for 24 h. The solution was concentrated under reduced pressure, and the crude residue was purified by column chromatography (SiO<sub>2</sub>, mixture of petroleum ether/ethyl acetate as eluent). *N*-benzyl-4-methylaniline **d4** was obtained as pale yellow oil (663 mg, 78%)

### Characterization of the products of the catalysis

*N*-benzylaniline<sup>2</sup> **d1** 

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d1** as a brown liquid (85.2 mg, 93% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.43 – 7.36 (m, 4H), 7.34 – 7.28 (m, 1H), 7.23 – 7.19 (m, 2H), 6.76 (td, *J* = 7.3, 1.1 Hz, 1H), 6.68 (d, *J* = 7.7 Hz, 2H), 4.36 (s, 2H), 4.08 (br, 1H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  148.2, 139.5, 129.4, 128.7, 127.6, 127.3, 117.7, 113.0, 48.5.

*N*-(2-methylbenzyl)aniline<sup>3</sup> d2

Following the general procedure, 2-methylbenzaldehyde (57.8  $\mu$ L, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d2** as a dark brown liquid (52.7 mg, 94% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.35 (d, J = 6.7 Hz, 1H), 7.26 – 7.17 (m, 5H), 6.74 (tt, J = 7.3, 1.1 Hz, 1H), 6.67 – 6.64 (m, 2H), 4.29 (s, 2H), 3.84 (s, 1H), 2.39 (s, 3H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  148.4, 137.1, 136.5, 130.5, 129.4, 128.4, 127.6, 126.3, 117.6, 112.8, 46.5, 19.1.

N-benzyl-4-methoxyaniline<sup>2</sup> d3

OMe

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and 4-methoxyaniline (73.9 mg, 0.6 mmol) gave the title compound **d3** as a brown solid (76.8 mg, 72% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.40 – 7.33 (m, 4H), 7.29 (d, *J* = 7.1 Hz, 1H), 6.81 – 6.77 (m, 2H), 6.64 – 6.60 (m, 2H), 4.30 (s, 2H), 3.75 (s, 3H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 152.4, 142.5, 139.8, 128.7, 127.7, 127.3, 115.0, 114.3, 55.9, 49.4.

*N*-benzyl-4-methylaniline<sup>2</sup> **d**4

Me

Following the specific procedure, benzaldehyde (475.0  $\mu$ L, 4.3 mmol) and 4-methylaniline (500.0 mg, 4.6 mmol) gave the title compound **d4** as a pale yellow oil (663 mg, 78% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.50 – 7.21 (m, 5H), 7.14 – 6.96 (m, 2H), 6.68 – 6.57 (m, 2H), 4.36 (s, 2H), 3.94 (s, 1H), 2.31 (s, 3H).

 $^{13}C{^{1}H} NMR (100.6 MHz, CDCl_3) \delta 146.0, 139.8, 129.9, 128.7, 127.6, 127.2, 126.8, 113.1, 48.7, 20.5.$ 

*N*-(4-methoxybenzyl)aniline<sup>2</sup> d5

Following the general procedure, 4-methoxybenzaldehyde (60.8  $\mu$ L, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d5** as a yellow liquid (92.8 mg, 87% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.30 (d, *J* = 8.6, 2H), 7.21 – 7.16 (m, 2H), 6.89 (d, *J* = 8.6 Hz, 2H), 6.73 (t, *J* = 7.3 Hz, 1H), 6.66 (dd, *J* = 7.7, 1.1 Hz, 2H), 4.27 (s, 2H), 3.81 (s, 3H).

 $^{13}C{^{1}H} NMR (100.6 \text{ MHz}, CDCl_{3}) \delta = 159.0, 148.2, 131.4, 129.4, 129.0, 117.8, 114.2, 113.1, 55.4, 48.0.$ 

N-benzyl-4-fluoroaniline<sup>2</sup> d6



Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and 4-fluoroaniline (57.6  $\mu$ L, 0.6 mmol) gave the title compound **d6** as a brown solid (28.2 mg, 28% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.39 – 7.26 (m, 5H), 6.89 (t, *J* = 8.7, 2H), 6.60 – 6.55 (m, 2H), 4.30 (s, 2H), 3.94 (br, 1H).

<sup>19</sup>F NMR (376.5 MHz, CDCl<sub>3</sub>) δ -127.91.

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 156.0 (d, <sup>1</sup>*J*<sub>CF</sub> = 235.0), 144.6 (d, *J*<sub>CF</sub> = 1.5 Hz), 139.4, 128.8, 127.6, 127.4, 115.8 (d, *J*<sub>CF</sub> = 22.3 Hz), 113.8 (d, *J*<sub>CF</sub> = 7.4 Hz), 49.1.

*N*-(3-fluorobenzyl)aniline<sup>4</sup> d7

Following the general procedure, 3-fluorobenzaldehyde (53.0  $\mu$ L, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d7** as a pale yellow solid (90.6 mg, 90% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  7.30 (td, *J* = 7.9, 7.3 Hz, 1H), 7.20-7.14 (m, 3H), 7.09 (dt, *J* = 9.8, 2.0 Hz, 1H), 6.96 (td, *J* = 8.4, 2.6 Hz, 1H), 6.74 (t, *J* = 7.3 Hz, 1H), 6.62 (d, *J* = 7.9 Hz, 2H), 4.35 (s, 2H), 4.09 (br, 1H).

 $^{19}\text{F}$  NMR (376 MHz, CDCl<sub>3</sub>)  $\delta\,$  -113.00.

<sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  163.2 (d, <sup>1</sup>*J*<sub>CF</sub> = 246.2 Hz), 147.9, 142.4 (d, *J*<sub>CF</sub> = 6.8 Hz), 130.2 (d, *J*<sub>CF</sub> = 8.2 Hz), 129.4, 122.9 (d, *J*<sub>CF</sub> = 2.8 Hz), 117.9, 114.4 (d, *J*<sub>CF</sub> = 8.3 Hz), 114.1 (d, *J*<sub>CF</sub> = 7.9 Hz), 113.0, 47.9.

GC-MS, m/z (%) = 201 ([M]+, 100), 109 (100), 77 (57), 65 (18), 51 (20).

N-(4-chlorobenzyl)aniline<sup>5</sup> d8

Following the general procedure, 4-chlorobenzaldehyde (70.3 mg, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d8** as a pale yellow liquid (87.1 mg, 80% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.31 (s, 4H), 7.18 (t, *J* = 7.9 Hz, 2H), 6.74 (t, *J* = 7.3 Hz, 1H), 6.62 (d, *J* = 7.8 Hz, 2H), 4.32 (s, 2H), 4.06 (br, 1H).

 $^{13}C{^{1}H} NMR (100.6 \text{ MHz}, CDCl_{3}) \delta 147.9, 138.1, 133.0, 129.4, 128.9, 128.8, 117.9, 113.0, 47.8.$ 

N-(4-bromobenzyl)-4-iodoaniline d9



Following the general procedure, 4-bromobenzaldehyde (92.5 mg, 0.5 mmol) and 4-iodoaniline (131.4 mg, 0.6 mmol) gave the title compound **d9** as a white solid (190.1 mg, 98% yield). The isolated product contains about 13% of 4-bromobenzylaniline<sup>4</sup> resulting from deiodination.

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.46 (d, *J* = 7.9, 2H), 7.41 (d, *J* = 8.1, 2H), 7.21 (d, *J* = 8.1, 2H), 6.38 (d, *J* = 8.2, 2H), 4.26 (s, 2H), 4.12 (br, 1H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ = 147.4, 138.03, 137.99, 131.9, 129.1, 121.3, 115.2, 78.6, 47.6.

GC-MS, m/z (%) = 389 ([M]+, 67), 308 (8), 169 (100), 90 (53), 76 (18), 63 (11), 50 (10).

*N*-benzyl-4-iodoaniline<sup>6</sup> **d10** 

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and 4-iodoaniline (131.4 mg, 0.6 mmol) gave the title compound **d10** as a brown liquid (149.9 mg, 97% yield). The isolated product contains about 10% of benzylaniline resulting from deiodination.

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.41 (d, *J* = 8.6 Hz, 2H), 7.37 – 7.34 (m, 5H), 6.42 (d, *J* = 8.6 Hz, 2H), 4.30 (d, *J* = 3.9 Hz, 2H), 4.10 (br, 1H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  147.8, 139.0, 137.9, 128.8, 127.6, 127.5, 115.2, 78.3, 48.2.

*N*,*N*-dimethyl-4-((*p*-tolylamino)methyl)aniline<sup>7</sup> **d11** 



Following the general procedure, 4-(dimethylamino)benzaldehyde (74.6 mg, 0.5 mmol) and *p*-toluidine (64.3 mg, 0.6 mmol) gave the title compound **d11** as a colorless solid (117.8 mg, 97% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.25 (d, *J* = 8.8 Hz, 2H), 6.99 (d, *J* = 7.9 Hz, 2H), 6.73 (d, *J* = 8.2 Hz, 2H), 6.58 (d, *J* = 8.0 Hz, 2H), 4.19 (s, 2H), 3.76 (br, 1H), 2.94 (s, 6H), 2.25 (s, 3H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  150.1, 146.4, 129.8, 128.8, 127.5, 126.6, 113.1, 112.9, 48.4, 40.9, 20.5.

Ethyl 4-((phenylamino)methyl)benzoate d12



Following the general procedure, methyl 4-formylbenzoate (82.1 mg, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d12** as a pale yellow liquid (117.4 mg, 92% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  8.02 (d, *J* = 8.2 Hz, 1H), 7.44 (d, *J* = 8.1 Hz, 2H), 7.17 (t, *J* = 7.9 Hz, 2H), 6.73 (t, *J* = 7.3 Hz, 1H), 6.61 (d, *J* = 8.1 Hz, 2H), 4.41 – 4.34 (m, 5H, *N*-CH<sub>2</sub>+CH<sub>2</sub>+NH), 1.39 (t, *J* = 7.1 Hz, 3H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 166.6, 147.9, 145.0, 130.0, 129.4, 127.2, 118.0, 113.0, 61.1, 48.1, 14.5.

GC-MS, m/z(%) = 255 ([M]+, 100), 226(24), 210(28), 182(49), 163(100), 135(60), 106(51), 89(34), 77(40), 65(10), 51(8).

N-(4-(((4-methoxyphenyl)amino)methyl)phenyl)acetamide<sup>2</sup> d13



Following the general procedure, *N*-(4-formylphenyl)acetamide (81.6 mg, 0.5 mmol) and 4-methoxyaniline (73.9, 0.6 mmol) gave the title compound **d13** as a pale yellow solid (128.4 mg, 95% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.45 (d, *J* = 8.3 Hz, 2H), 7.31 (d, *J* = 8.2 Hz, 2H), 6.77 (d, *J* = 8.9 Hz, 2H), 6.59 (d, *J* = 8.9 Hz, 2H), 4.24 (s, 2H), 3.74 (s, 3H), 2.16 (s, 3H), 1.67 (br, 1H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 168.4, 152.3, 142.5, 137.0, 135.8, 128.3, 120.3, 115.0, 114.3, 56.0, 48.9, 24.7.

N-(4-(1-(phenylimino)ethyl)benzyl)aniline d14



Following the general procedure, 4-acetylbenzaldehyde (74.1 mg, 0.5 mmol) and aniline (100.4  $\mu$ L, 1.1 mmol) gave the title compound **d14** as a dark brown liquid (132.2 mg, 88% yield, 95% purity).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  7.96 (d, *J* = 8.3 Hz, 2H), 7.45 (d, *J* = 8.1 Hz, 2H), 7.36 (t, *J* = 7.8 Hz, 2H), 7.18 (t, *J* = 7.3 Hz, 2H), 7.09 (t, *J* = 7.3 Hz, 1H), 6.80 (d, *J* = 7.3 Hz, 2H), 6.74 (t, *J* = 7.3 Hz, 1H), 6.64 (d, *J* = 7.8 Hz, 2H), 4.41 (s, 2H), 4.12 (br, 1H), 2.23 (s, 3H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  165.3, 151.8, 148.1, 142.3, 138.7, 129.4, 129.1, 127.7, 127.4, 123.3, 119.5, 117.9, 113.1, 48.1, 17.5.

GC-MS, m/z(%) = 300 ([M]+, 100), 285(23), 208(68), 193(33), 143(17), 116(15), 105(88), 90(30), 77(55), 51(14)

1-(4-((Phenylamino)methyl)phenyl)ethan-1-one<sup>8</sup> d15



Following the general procedure, 4-acetylbenzaldehyde (74.1 mg, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d15** as a pale yellow solid (82.2 mg, 73% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.93 (d, *J* = 8.2 Hz, 2H), 7.47 (d, *J* = 8.2 Hz, 2H), 7.17 (dd, *J* = 8.6, 7.2 Hz, 2H), 6.73 (t, *J* = 7.3 Hz, 1H), 6.61 (d, *J* = 7.7 Hz, 2H), 4.42 (s, 2H), 4.19 (s, br, 1H), 2.59 (s, 3H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 197.9, 147.8, 145.3, 136.3, 129.4, 128.9, 127.4, 118.0, 113.1, 48.1, 26.7.

1-(4-(Benzylamino)phenyl)ethan-1-one<sup>9</sup> d16

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and 4-amino acetophenone (67.6 mg, 0.5 mmol) gave the title compound **d16** as a pale yellow solid (108.1 mg, 96% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.82 (d, *J* = 8.6 Hz, 2H), 7.38 – 7.30 (m, 5H), 6.60 (d, *J* = 8.6 Hz, 2H), 4.58 (br, 1H), 4.41 (d, *J* = 5.5 Hz, 2H), 2.49 (s, 3H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  196.5, 152.1, 138.4, 130.9, 128.9, 127.6, 127.4, 127.0, 111.7, 47.6, 26.1.

N-(ferrocenylmethyl)-4-methylaniline<sup>7</sup> d17



Following the general procedure, ferrocenecarboxaldehyde (107.0 mg, 0.5 mmol) and *p*-toluidine (64.3 mg, 0.6 mmol) gave the title compound **d17** as a dark brown liquid (149.5 mg, 98% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.02 (d, *J* = 8.1 Hz, 2H), 6.60 (d, *J* = 8.3 Hz, 2H), 4.24 (t, *J* = 1.9 Hz, 2H), 4.18 (s, 5H), 4.14 (t, *J* = 1.8 Hz, 2H), 3.94 (s, 2H), 3.75 (br, 1H), 2.26 (s, 3H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 146.3, 129.9, 126.9, 113.2, 86.9, 68.6, 68.2, 68.0, 43.9, 20.6.

4-Methoxy-*N*-((1-methyl-1H-pyrrol-2-yl)methyl)aniline<sup>7</sup> d18



Following the general procedure, 1-methyl-1*H*-pyrrole-2-carbaldehyde (53.7  $\mu$ L, 0.5 mmol) and 4-methoxyaniline (73.9 mg, 0.6 mmol) gave the title compound **d18** as a dark brown liquid (104.9 mg, 97% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 6.84 – 6.79 (m, 2H), 6.67 – 6.66 (m, 2H), 6.63 – 6.62 (m, 1H), 6.12 – 6.11 (m, 1H), 6.08 (t, *J* = 3.1 Hz, 1H), 4.17 (s, 2H), 3.76 (s, 3H), 3.64 (s, 3H), 3.41 (br, 1H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 152.5, 142.6, 130.1, 122.9, 115.1, 114.4, 108.5, 106.9, 56.0, 41.5, 33.9.

4-Methoxy-N-((5-methylfuran-2-yl)methyl)aniline<sup>7</sup> d19



Following the general procedure, 5-methylfuran-2-carbaldehyde (50.1  $\mu$ L, 0.5 mmol) and 4-methoxyaniline (73.9 mg, 0.6 mmol) gave the title compound **d19** as a brown solid (97.8 mg, 90% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 6.79 (d, *J* = 8.9 Hz, 2H), 6.65 (d, *J* = 8.8 Hz, 2H), 6.09 (d, *J* = 3.0 Hz, 1H), 5.98 (d, *J* = 2.5 Hz, 1H), 4.21 (s, 2H), 3.75 (s, 4H, OCH<sub>3</sub>+NH), 2.28 (s, 3H).

 $^{13}\text{C}\{^{1}\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  152.7, 151.7, 151.2, 142.1, 115.0, 114.8, 107.9, 106.2, 55.9, 42.7, 13.7.

*N*-(pyridin-2-ylmethyl)aniline<sup>3</sup> d20

Following the general procedure, pyridine-2-carboxaldehyde (47.6  $\mu$ L, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d20** as a brown liquid (62.6 mg, 68% yield, 90% purity by <sup>1</sup>H NMR).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  8.59 (d, *J* = 4.8 Hz, 1H), 7.63 (td, *J* = 7.7, 1.8 Hz, 1H), 7.34 (d, *J* = 7.8 Hz, 1H), 7.21 – 7.16 (m, 3H), 6.73 (tt, *J* = 7.4, 1.1 Hz, 1H), 6.69 – 6.66 (m, 2H), 4.84 (br, 1H), 4.47 (s, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  158.6, 149.2, 147.9, 136.7, 129.3, 122.2, 121.7, 117.6, 113.1, 49.3.

N-benzylpyridin-2-amine<sup>5</sup> d21

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and 2-aninopyridine (56.5 mg, 0.6 mmol) gave the title compound **d21** as a colorless solid (50.7 mg, 55% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  8.12 (ddd, *J* = 5.0, 2.0, 0.9 Hz, 1H), 7.44 – 7.34 (m, 5H), 7.32-7.28 (m, 1H), 6.61 (ddd, *J* = 7.1, 5.0, 0.9 Hz, 1H), 6.39 (dt, *J* = 8.3, 1.0 Hz, 1H), 5.05 (s, 1H), 4.53 (d, *J* = 5.8 Hz, 2H).

 $^{13}C{^{1}H} NMR (100.6 MHz, CDCl_3) \delta 158.8, 148.3, 139.3, 137.6, 128.7, 127.5, 127.3, 113.2, 106.9, 46.4.$ 

2-(Benzylamino)thiophene-3-carbonitrile d22



Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and 2-aminothiophene- 3-carbonitrile (74.5 mg, 0.6 mmol) gave the title compound **d22** as a dark green solid (96.4 mg, 90% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  7.41 – 7.30 (m, 5H), 6.78 (d, J = 5.7 Hz, 1H), 6.29 (d, J = 5.7 Hz, 1H), 5.57 (br, 1H), 4.41 (s, 2H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 165.3, 136.6, 128.9, 128.2, 127.8, 126.1, 116.4, 108.7, 84.5, 51.8.

GC-MS, m/z(%) = 214 ([M]+, 19), 91(100), 65(15).

*N*-benzyl-5-methylthiazol-2-amine<sup>10</sup> d23

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and 5-methylthiazol- 2-amine (68.5 mg, 0.6 mmol) gave the title compound **d23** as a colorless solid (94.0 mg, 92% yield, 95% purity).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.38 – 7.26 (m, 5H), 6.65 (s, 1H), 6.28 (br, 1H), 4.42 (s, 2H), 2.26 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 169.2, 138.0, 135.3, 128.7, 127.74, 127.66, 121.0, 49.9, 12.1. N-(4-bromobenzyl)benzenesulfonamide d24

Following the general procedure, 4-bromobenzaldehyde (92.5 mg, 0.5 mmol) and benzenesulfonamide (94.3 mg, 0.6 mmol) gave the title compound **d24** as a white solid (151.7 mg, 93% yield, 90% purity).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  7.81 (d, *J* = 7.6 Hz, 2H), 7.57 (t, *J* = 7.4 Hz, 1H), 7.47 (t, *J* = 7.7 Hz, 2H), 7.34 (d, *J* = 8.3 Hz, 2H), 7.04 (d, *J* = 8.2 Hz, 2H), 5.43 (t, *J* = 6.4 Hz, 1H), 4.06 (d, *J* = 5.8 Hz, 2H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 139.9, 135.5, 132.9, 131.9, 129.6, 129.3, 127.2, 121.9, 46.7.

GC-MS, m/z(%) = 325 ([M]+, 0.5), 246(0.5), 184(100), 157(10), 143(20), 125(11), 104(10), 90(13), 77(91), 51(31).

Dibenzylamine<sup>2</sup> d25

N H

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and benzylamine (65.5  $\mu$ L, 0.6 mmol) gave the title compound **d25** as a pale yellow liquid (88.8 mg, 90% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.38 – 7.26 (m, 10H), 3.84 (s, 4H), 1.91 (br, 1H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  140.4, 128.5, 128.3, 127.1, 53.3.

*N*-benzyldodecan-1-amine<sup>11</sup> **d26** 

N

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and dodecylamine (111.2 mg, 0.6 mmol) gave the title compound **d26** as a pale yellow liquid (130.9 mg, 95% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.37 – 7.22 (m, 5H), 3.79 (s, 2H), 2.63 (t, *J* = 7.0 Hz, 2H), 1.58 -1.47 (m, 2H), 1.35 –1.26 (m, 20H), 0.88 (t, *J* = 6.8 Hz, 3H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 140.7, 128.5, 128.3, 127.0, 54.2, 49.7, 32.1, 30.3, 29.81, 29.79, 29.76, 29.72, 29.5, 27.5, 22.8, 14.3.

*N*-benzylcyclohexanamine<sup>12</sup> **d27** 

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and cyclohexanamine (68.8  $\mu$ L, 0.6 mmol) gave the title compound **d27** as a pale yellow liquid (89.0 mg, 94% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.35 – 7.22 (m, 5H), 3.82 (s, 2H), 2.52 – 2.47 (m, 1H), 1.93 – 1.91 (m, 2H), 1.76 – 1.71 (m, 2H), 1.64 – 1.59 (m, 1H), 1.42 (br, 1H), 1.31 – 1.08 (m, 5H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 141.1, 128.5, 128.2, 126.9, 56.3, 51.2, 33.7, 26.3, 25.2.

Tribenzylamine<sup>13</sup> d28

N Ph Ph

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and dibenzylamine (116.1  $\mu$ L, 0.6 mmol) gave the title compound **d28** as a pale yellow solid (138.0 mg, 96% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.47 (d, *J* = 7.5 Hz, 6H), 7.37 (t, *J* = 7.4 Hz, 6H), 7.29 (d, *J* = 7.2 Hz, 3H), 3.62 (s, 6H).

 $^{13}C{^{1}H} NMR (100.6 MHz, CDCI_{3}) \delta 139.8, 128.9, 128.3, 127.0, 58.1.$ 

N-benzyl-N-ethylethanamine<sup>14</sup> d29

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and diethylamine (61.8  $\mu$ L, 0.6 mmol) gave the title compound **d29** as a pale yellow liquid (76.7 mg, 94% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.38 – 7.21 (m, 5H), 3.57 (s, 2H), 2.52 (q, *J* = 7.1 Hz, 4H), 1.04 (t, *J* = 7.1 Hz, 6H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 138.8, 129.3, 128.3, 127.1, 57.2, 46.5, 11.4.

#### 1-Benzylpiperidine<sup>13</sup> d30



Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and piperidine (59.3  $\mu$ L, 0.6 mmol) gave the title compound **d30** as a pale yellow liquid (81.5 mg, 93% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.39 – 7.28 (m, 5H), 3.53 (s, 2H), 2.50 – 2.41 (m, 4H), 1.63 – 1.57 (m, 4H), 1.45 – 1.43 (m, 2H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  138.0, 129.6, 128.3, 127.2, 63.7, 54.4, 25.9, 24.4.

*N*,*N*'-dibenzylethane-1,2-diamine<sup>15</sup> **d31** 

Following the general procedure, benzaldehyde (122.4  $\mu$ L, 1.2 mmol) and ethane-1,2-diamine (33.5  $\mu$ L, 0.5 mmol) gave the title compound **d31** as a pale yellow solid (114.2 mg, 95% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.37-7.25 (m, 10H), 3.81 (s, 4H), 2.79 (s, 4H), 1.86 (s, 2H, NH).

 $^{13}C{^{1}H} NMR (100.6 MHz, CDCl_3) \delta 140.5, 128.5, 128.2, 127.0, 54.0, 48.8.$ 

2-(Benzylamino)ethan-1-ol<sup>16</sup> d32

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and 2-aminoethan-1-ol (30.0  $\mu$ L, 0.5 mmol) gave the title compound **d32** as a pale yellow liquid (65.0 mg, 86% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.35 – 7.23 (m, 5H), 3.81 (s, 2H), 3.65 (t, *J* = 5.2 Hz, 2H), 2.80 (t, *J* = 5.2 Hz, 2H), 2.07 (br, 2H, NH + OH + H<sub>2</sub>O).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  140.1, 128.6, 128.3, 127.2, 61.1, 53.6, 50.7.

3-(Benzylamino)propan-1-ol d33

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and 3-aminopropan-1-ol (38.2  $\mu$ L, 0.5 mmol) gave the title compound **d33** as a colorless liquid (68.6 mg, 83% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.35 – 7.23 (m, 5H), 3.81 (t, *J* = 5.2, 2H), 3.79 (s, 2H), 2.89 (t, *J* = 5.8 Hz, 2H), 2.81 (br, 2H), 1.72 (quint., *J* = 5.5 Hz, 2H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ = 139.7, 128.6, 128.3, 127.3, 64.4, 54.1, 49.5, 30.9.

GC-MS, m/z(%) = 165([M]+, 2), 120(50), 106(19), 91(100), 77(3), 65(9).

(R)-2-(Benzylamino)butan-1-ol<sup>17</sup> d34

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and (*R*)-2-amino-1-butanol (CAS: 5856-63-3, 47.5  $\mu$ L, 0.5 mmol) gave the title compound **d34** as a white solid (86.9 mg, 97% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.37 – 7.24 (m, 5H), 3.91 – 3.79 (m, 2H), 3.67 – 3.65 (m, 1H), 3.34 (br, 1H), 2.64 (br, 1H), 1.56 – 1.42 (m, 2H), 0.93 (t, *J* = 6.8, 3H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 140.5, 128.6, 128.2, 127.2, 62.7, 59.8, 51.2, 24.5, 10.5.

 $[\alpha]_{D}^{20}$  = -30.61 (*C* 0.5, CH<sub>2</sub>Cl<sub>2</sub>).

Ethyl (R)-2-(benzylamino)-2-phenylacetate<sup>18</sup> d35

(*R*)-2-Phenylglycinemethyl ester hydrochloride (CAS: 19883-41-1, 121.0 mg, 0.6 mmol) was added into an Et<sub>3</sub>N (111.5  $\mu$ L, 0.8 mmol) solution in THF (5.0 mL) and stirred for 2 h. The solution was filtered through celite then washed with ethyl acetate (3×2.0 mL). The filtrate was evaporated to dryness to afford (*R*)-2-phenylglycinemethyl ester, which was used for the following step without further purification.

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and (*R*)-2-phenylglycinemethyl ester hydrochloride (121.0 mg, 0.6 mmol) gave the title compound **d35** as a pale yellow liquid (121.2 mg, 90% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.41 – 7.24 (m, 10H), 4.39 (s, 1H), 4.24 – 4.09 (m, 2H), 3.75 (s, 2H), 1.21 (t, *J* = 7.0 Hz, 3H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  173.1, 139.6, 138.3, 128.7, 128.5, 128.4, 128.1, 127.6, 127.2, 64.5, 61.2, 51.5, 14.2.

 $[\alpha]_{D}^{20}$  = -4.98 (*C* 1.2, CH<sub>2</sub>Cl<sub>2</sub>)

Ethyl benzyl-L-alaninate<sup>19</sup> d36

L-Alanine ethyl ester hydrochloride (CAS: 1115-59-9, 92.2 mg, 0.6 mmol) was added into an Et<sub>3</sub>N (111.5  $\mu$ L, 0.8 mmol) solution in THF (5.0 mL) and stirred for 2 h. The solution was filtered through celite then washed with ethyl acetate (3×2.0 mL mL). The filtrate was evaporated to dryness to afford L-alanine ethyl ester, which was used for the following step without further purification.

Following the general procedure, benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and L-alanine ethyl ester hydrochloride (92.2 mg, 0.6 mmol) gave the title compound **d36** as a pale yellow liquid (94.3 mg, 91% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.34– 7.22 (m, 5H), 4.19 (q, *J* = 7.1, 2H), 3.83 – 3.66 (m, 2H), 3.40 – 3.38 (m, 1H), 2.10 (br, 1H), 1.32 (d, *J* = 6.3, 3H), 1.29 (t, *J* = 7.0, 4H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  = 175.9, 139.7, 128.5, 128.4, 127.2, 60.8, 56.0, 52.2, 19.2, 14.4.

 $[\alpha]_{D}^{20}$  = + 3.17 (*C* 0.9, CH<sub>2</sub>Cl<sub>2</sub>)

N-butyldodecan-1-amine d37

Following the general procedure, butyraldehyde (45.1  $\mu$ L, 0.5 mmol) and dodecylamine (111.2 mg, 0.6 mmol) gave the title compound **d37** as a yellow-green liquid (115.9 mg, 96% yield). This compound was further purified by bulb to bulb distillation.

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 2.59 (m, 4H), 1.70 - 1.12 (m, 25H), 0.93 - 0.86 (m, 6H).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 50.3, 49.9, 32.4, 32.1, 30.2, 29.82, 29.79, 29.77, 29.74, 29.5, 27.6, 22.8, 20.7, 14.27, 14.18.

GC-MS, m/z(%) = 241 ([M]+, 25), 198(100), 184(9), 142(9), 87(100), 70(11), 57(27).

N-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)aniline d38



Following the general procedure, 5-norbornene-2-carboxaldehyde (52.6  $\mu$ L, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d38** as mixture of *endo/exo* isomers as a brown liquid (94.7mg, 95% yield).

*M* = Major isomer *endo*, *m* = minor isomer *exo*, ratio *M*:*m* = 60:40

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  7.20-7.16 (m, 2H, *M* + *m*, CH<sub>Ar</sub>), 6.75 – 6.66 (m, 1H, *M* + *m*, CH<sub>Ar</sub>), 6.64 – 6.58 (m, 2H, CH<sub>Ar</sub>), 6.19 (dd, *J* = 5.7, 3.0 Hz, 1H, *M*, CH=CH), 6.15 – 6.02 (m, 2H, *m*, CH=CH), 5.97 (dd, *J* = 5.8, 2.9 Hz, 1H, *M*, CH=CH), 3.18 (dd, *J* = 11.9, 6.9 Hz, 1H, *m*, CH<sub>2</sub>N), 3.09 (dd, *J* = 11.9, 8.3 Hz, 1H, *m*, CH<sub>2</sub>N), 2.92 (br s, 1H, *M*, CH), 2.90 – 2.76 (m, 4H, *M*, CH<sub>2</sub>N +CH, m, CH), 2.73 (br s, 1H, *m*, CH), 2.36 (m, 1H, *M*, CH), 1.92 (ddd, *J* = 11.5, 9.1, 3.9 Hz, 1H, *M*, CH<sub>2</sub>), 1.76 – 1.64 (m, 1H, *m*, CH), 1.47 (dd, *J* = 8.2, 2.2 Hz, 1H, *M*, CH<sub>2</sub>), 1.44 – 1.33 (m, 3H, *m*, CH<sub>2</sub>), 1.28 (dt, *J* = 8.3, 1.6 Hz, 1H, *M*, CH<sub>2</sub>), 1.23 (dt, *J* = 11.6, 3.8 Hz, 1H, *m*, CH<sub>2</sub>), 0.64 (ddd, *J* = 11.5, 4.4, 2.6 Hz, 1H, *M*, CH<sub>2</sub>).

<sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, CDCl<sub>3</sub>) δ 148.69 (C<sub>qAr</sub>, *M*), 148.63 (C<sub>qAr</sub>, *m*), 137.76 (*M*, CH=CH), 136.91 (*m*, CH=CH), 136.56 (*m*, CH=CH), 132.19 (*M*, CH=CH), 129.37 (*m*, CH<sub>Ar</sub>), 129.34 (*M*, CH<sub>Ar</sub>), 117.24 (*m*, CHAr), 117.20 (*M*, CH<sub>Ar</sub>), 112.83 (*M*, CH<sub>Ar</sub>), 112.78 (*m*, CH<sub>Ar</sub>), 49.72 (*m*, CH<sub>2</sub>), 49.70 (*M*, CH<sub>2</sub>), 48.33 (*M*, CH<sub>2</sub>), 45.39 (*m*, CH<sub>2</sub>), 44.63 (*m*, CH), 44.38 (*M*, CH), 42.53 (*M*, CH), 41.83 (*m*, CH), 39.14 (*m*, CH), 38.87 (*M*, CH), 31.41 (*m*, CH<sub>2</sub>), 30.59 (*M*, CH<sub>2</sub>).

GC-MS, m/z(%) = 199([M]+, 47), 158(12), 132(88), 106(100), 91(13), 77(42), 65(13), 51(13)

N-(2,6-dimethylhept-5-en-1-yl)aniline d39

Following the general procedure, 2,6-dimethyl-5-heptenal (84.2  $\mu$ L, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d39** as a brown liquid (104.3 mg, 96% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>)  $\delta$  7.17 (td, *J* = 7.4, 1.8 Hz, 2H), 6.68 (tt, *J* = 7.3, 1.1 Hz, 1H), 6.60 (dd, *J* = 8.6, 1.1 Hz, 2H), 5.11 (m, 1H), 3.70 (br, 1H), 3.06 (dd, *J* = 12.2, 5.9 Hz, 1H), 2.89 (dd, *J* = 12.2, 7.3 Hz, 1H), 2.14 - 1.94 (m, 2H), 1.82 - 1.72 (m, 1H), 1.69 (s, 3H), 1.62 (s, 3H), 1.54 - 1.42 (m, 1H), 1.32 - 1.08 (m, 1H), 0.99 (d, *J* = 6.7, 3H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  148.77, 131.71, 129.35, 124.64, 117.07, 112.77, 50.40, 35.02, 32.70, 25.87, 25.59, 18.17, 17.85.

GC-MS, m/z(%) = 217([M]+, 60), 146(100), 133(10), 106(95), 93(20), 77(35), 69(9), 51(9).

N-(3-phenylpropyl)aniline<sup>20</sup> d40

Following the general procedure cinnamaldehyde (62.9  $\mu$ L, 0.5 mmol) and aniline (54.8  $\mu$ L, 0.6 mmol) gave the title compound **d40** as pale yellow liquid (98.3 mg, 93% yield).

<sup>1</sup>H NMR (400.1 MHz, CDCl<sub>3</sub>) δ 7.36 – 7.11 (m, 7H), 6.70 (t, *J* = 7.3 Hz, 1H), 6.59 (d, *J* = 7.9 Hz, 2H), 3.62 (s, 1H), 3.16 (t, *J* = 7.0 Hz, 2H), 2.75 (t, *J* = 7.5 Hz, 2H), 1.97 (p, *J* = 7.2 Hz, 2H).

 $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz, CDCl\_3)  $\delta$  148.5, 141.8, 129.4, 128.6, 128.5, 126.1, 117.3, 112.9, 43.6, 33.5, 31.2.

# Supplementary tables

	2 (5 mol%), <i>t</i> BuOK (10 mol%) → H <sub>2</sub> (50 bar), solvent, heat, 20 h	NH d1	
Entry	Temp. (°C)	Solvent	Yield (%)
1	130	Toluene	48
2	130	t-amyl alcohol	81
3	130	Dimethyl carbonate	84
4	130	THF	95
5	130	1,4-dioxane	40
6	130	CPME	43
7	100	THF	71
8	100	t-amyl alcohol	28
9	100	EtOH	98
10	100	<i>n</i> -BuOH	95
11	100	MeOH	84

Table S1. Hydrogenation of benzylideneaniline: influence of the solvent.<sup>[a]</sup>

[a] Conditions: An autoclave was charged in a glovebox with, in this order, **c1** (45.3 mg, 0.25 mmol), solvent (2.0 mL), **2** (6.2 mg, 5.0 mol%), *t*BuOK (2.8 mg, 10 mol%), and then pressurized with  $H_2$  (50 bar) and heated at the indicated temperature. Yield determined by GC and <sup>1</sup>H NMR spectroscopy.

C c1	<b>2</b> (1 mol%), <i>base</i> (2 mol%) H <sub>2</sub> (50 bar), EtOH, 100 °C, 5	$\stackrel{6)}{22 h} \qquad $
Entry	Base (mol%)	Yield (%)
1	<i>t</i> BuOK (2)	64
2	<i>t</i> BuONa (2)	50
3	Cs <sub>2</sub> CO <sub>3</sub> (2)	57
4	KHMDS (2)	41

**Table S2**. Hydrogenation of benzylideneaniline: influence of the base.<sup>[a]</sup>

[a] Conditions: An autoclave was charged in a glovebox with, in this order, **c1** (90.6 mg, 0.5 mmol), anhydrous ethanol (2.0 mL), **2** (2.5 mg, 1.0 mol%), base (2 mol%), and then pressurized with  $H_2$  (50 bar) and heated at 100 °C. Yield determined by GC and <sup>1</sup>H NMR spectroscopy.

C c1	<b>[Mn]</b> , <i>base</i> H <sub>2</sub> , EtOH, 50 °C, 22 h	NH d1		
Entry	Catalyst (mol%)	Base (mol%)	H <sub>2</sub> (bar)	Yield (%)
1	-	tBuOK (5)	50	< 1
2	2 (2)	-	50	3
3	2 (2)	tBuOK (5)	25	87

Table S3. Hydrogenation of benzylideneaniline: control experiments.<sup>[a]</sup>

[a] Conditions: An autoclave was charged in a glovebox with, in this order, **c1** (90.6 mg, 0.5 mmol), anhydrous ethanol (2.0 mL), **2** (5.0 mg, 2.0 mol%), *t*BuOK (2.8 mg, 5 mol%), and then pressurized with  $H_2$  (50 or 25 bar) and heated at 50 °C. Yield determined by GC and 1H NMR spectroscopy.

**Table S4**. Optimization of the procedure for reductive amination of benzaldehyde with aniline in the presence of manganese precatalyst complex **2** 



Conditions A: an autoclave was charged with **2** (5.0 mg, 2 mol%), anhydrous ethanol (2.0 mL), aniline (46  $\mu$ L, 0.5 mmol), benzaldehyde (51.0  $\mu$ L, 0.5 mmol), *t*BuOK (2.8 mg, 5 mol%) and H<sub>2</sub> (50 bar) and heated at 80 °C for 20 h.

Conditions B: an autoclave was charged with **2** (5.0 mg, 2 mol%), anhydrous ethanol (2.0 mL), aniline (46  $\mu$ L, 0.5 mmol), benzaldehyde (51.0  $\mu$ L, 0.5 mmol) and *t*BuOK (2.8 mg, 5 mol%). After heating at 80 °C for 5 h, H<sub>2</sub> (50 bar) was charged and the mixture heated at 80 °C for 20 h.

Conditions C: in a 20 mL Schlenk tube aniline (46  $\mu$ L, 0.5 mmol) and benzaldehyde (51.0  $\mu$ L, 0.5 mmol) in anhydrous ethanol (2.0 mL) were heated at 100 °C for 24 h. The reaction mixture was transferred into an autoclave followed by **2** (5.0 mg, 2 mol%), *t*BuOK (2.8 mg, 5 mol%) and H<sub>2</sub> (50 bar), then heated at 80 °C for 20 h.

 Table S5. Hydrogenation of ketimine.



[a] Conditions: an autoclave was charged in a glovebox with, in this order, ketimine (119.7 mg, 0.5 mmol), anhydrous ethanol (2.0 mL), **2** (2.0 or 5.0 mol%), *t*BuOK (5 or 10 mol%), pressurized with  $H_2$  (50 bar), then heated at the indicated temperature.

# NMR Spectra of the products of reductive amination



Figure S1: <sup>1</sup>H NMR spectrum of the compound d1 in CDCl<sub>3</sub> recorded at 400.1 MHz.



Figure S2:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound d1 in CDCl<sub>3</sub> recorded at 100.6 MHz.





19.08

46.51

137.12 136.48 130.54 129.41 128.39 127.55 126.29

148.42

117.58 112.80



Figure S5: <sup>1</sup>H NMR spectrum of the compound d3 in CDCl<sub>3</sub> recorded at 400.1 MHz.



Figure S6:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound d3 in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S8:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound d4 in CDCl<sub>3</sub> recorded at 100.6 MHz.





Figure S10: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d5 in CDCl<sub>3</sub> recorded at 100.6 MHz.









Figure S12: <sup>19</sup>F NMR spectrum of the compound d6 in CDCl<sub>3</sub> recorded at 376.5 MHz.



Figure S14: <sup>1</sup>H NMR spectrum of the compound d7 in CDCl<sub>3</sub> recorded at 400.1 MHz.



40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 -260 -280 -300 -320 -340 f1 (ppm)

Figure S15:  $^{19}\mathsf{F}$  NMR spectrum of the compound d7 in CDCl3 recorded at 376.5 MHz.



Figure S16:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound d7 in CDCl<sub>3</sub> recorded at 100.6 MHz.







Figure S18: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d8 in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S20: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d9 in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S22:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound d10 in CDCl<sub>3</sub> recorded at 100.6 MHz.







Figure S24: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d11 in CDCl<sub>3</sub> recorded at 100.6 MHz.





147.91 144.96

166.60

48.15

61.05

14.48



Figure S27: <sup>1</sup>H NMR spectrum of the compound d13 in CDCl<sub>3</sub> recorded at 400.1 MHz.



Figure S28: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d13 in CDCl<sub>3</sub> recorded at 100.6 MHz.





Figure S30: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d14 in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S31: <sup>1</sup>H NMR spectrum of the compound d15 in CDCl<sub>3</sub> recorded at 400.1 MHz.



**Figure S32**: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound **d15** in CDCl<sub>3</sub> recorded at 100.6 MHz.





Figure S34: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d16 in CDCl<sub>3</sub> recorded at 100.6 MHz.

Ν̈́





Figure S37: <sup>1</sup>H NMR spectrum of the compound d18 in  $CDCl_3$  recorded at 400.1 MHz.



**Figure S38**:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound **d18** in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S39: <sup>1</sup>H NMR spectrum of the compound d19 in CDCl<sub>3</sub> recorded at 400.1 MHz.



Figure S40: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d19 in CDCl<sub>3</sub> recorded at 100.6 MHz.







Figure S42: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d20 in CDCl<sub>3</sub> recorded at 100.6 MHz.







Figure S44: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d21 in CDCl<sub>3</sub> recorded at 100.6 MHz.







Figure S46: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d22 in CDCl<sub>3</sub> recorded at 100.6 MHz.

















Figure S51: <sup>1</sup>H NMR spectrum of the compound d25 in CDCl<sub>3</sub> recorded at 400.1 MHz.



**Figure S52**:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound **d25** in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S54: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d26 in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S56: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d27 in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S58: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d28 in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S60: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d29 in CDCl<sub>3</sub> recorded at 100.6 MHz.







Figure S62:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound d30 in CDCl<sub>3</sub> recorded at 100.6 MHz.



**Figure S64**:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound **d31** in CDCl<sub>3</sub> recorded at 100.6 MHz.









Figure S66:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound d32 in CDCl<sub>3</sub> recorded at 100.6 MHz.







**Figure S68**: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound **d33** in CDCl<sub>3</sub> recorded at 100.6 MHz.





Figure S70: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d34 in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S71: <sup>1</sup>H NMR spectrum of the compound d35 in CDCl<sub>3</sub> recorded at 400.1 MHz.



**Figure S72**:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound **d35** in CDCl<sub>3</sub> recorded at 100.6 MHz.





Figure S74:  $^{13}C\{^{1}H\}$  NMR spectrum of the compound d36 in CDCl<sub>3</sub> recorded at 100.6 MHz.





Figure S76: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d37 in CDCl<sub>3</sub> recorded at 100.6 MHz.









Figure S78: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d38 in CDCl<sub>3</sub> recorded at 100.6 MHz.





Figure S80:  ${}^{13}C{}^{1}H$  NMR spectrum of the compound d39 in CDCl<sub>3</sub> recorded at 100.6 MHz.



Figure S81: <sup>1</sup>H NMR spectrum of the compound d40 in CDCl<sub>3</sub> recorded at 400.1 MHz.



Figure S82: <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of the compound d40 in CDCl<sub>3</sub> recorded at 100.6 MHz.

#### References

- 1. D. Wei, A. Bruneau-Voisine, T. Chauvin, V. Dorcet, T. Roisnel, D. Valyaev, N. Lugan and J.-B. Sortais, *Adv. Synth. Catal.*, 2018, **360**, 676-681.
- 2. J. Zheng, T. Roisnel, C. Darcel and J. B. Sortais, *ChemCatChem*, 2013, 5, 2861-2864.
- 3. M. Zhang, H. Yang, Y. Zhang, C. Zhu, W. Li, Y. Cheng and H. Hu, *Chem. Commun.*, 2011, **47**, 6605-6607.
- 4. P. Liu, R. Liang, L. Lu, Z. Yu and F. Li, J. Org. Chem., 2017, 82, 1943-1950.
- 5. D. B. Bagal, R. A. Watile, M. V. Khedkar, K. P. Dhake and B. M. Bhanage, *Catal. Sci. Technol.*, 2012, **2**, 354-358.
- 6. M. Yang and F. Liu, J. Org. Chem., 2007, 72, 8969-8971.
- 7. L. P. Bheeter, M. Henrion, M. J. Chetcuti, C. Darcel, V. Ritleng and J.-B. Sortais, *Catal. Sci. Technol.*, 2013, **3**, 3111-3116.
- 8. R. Cano, M. Yus and D. J. Ramón, *Tetrahedron*, 2011, **67**, 8079-8085.
- 9. C. T. Yang, Y. Fu, Y. B. Huang, J. Yi, Q. X. Guo and L. Liu, Angew. Chem., 2009, 121, 7534-7537.
- 10. R. Cano, D. J. Ramon and M. Yus, J. Org. Chem., 2011, 76, 5547-5557.
- 11. P. R. Likhar, R. Arundhathi, M. L. Kantam and P. S. Prathima, *Eur. J. Org. Chem.*, 2009, **2009**, 5383-5389.
- 12. L. C. M. Castro, J.-B. Sortais and C. Darcel, Chem. Commun., 2012, 48, 151-153.
- 13. T. Dombray, C. Helleu, C. Darcel and J. B. Sortais, Adv. Synth. Catal., 2013, 355, 3358-3362.
- 14. L. Blackburn and R. J. K. Taylor, Org. Lett., 2001, 3, 1637-1639.
- 15. S. Lateef, S. Reddy Krishna Mohan and S. Reddy Jayarama Reddy, *Tetrahedron Lett.*, 2007, **48**, 77-80.
- 16. M. Largeron and M.-B. Fleury, Org. Lett., 2009, 11, 883-886.
- 17. (a) Y. Turgut, N. Demirel and H. Hoşgören, J. Incl. Phenom. Macrocycl. Chem., 2006, 1, 29-33; (b)
  H. Bräuner-Osborne, L. Bunch, N. Chopin, F. Couty, G. Evano, A. A. Jensen, M. Kusk, B. Nielsen and N. Rabasso, Org. Biomol. Chem., 2005, 3, 3926-3936.
- 18. Q.-H. Deng, H.-W. Xu, A. W.-H. Yuen, Z.-J. Xu and C.-M. Che, Org. Lett., 2008, 10, 1529-1532.
- 19. B. T. Cho and S. K. Kang, *Tetrahedron*, 2005, **61**, 5725-5734.
- 20. R. Kubiak, I. Prochnow and S. Doye, Angew. Chem. Int. Ed., 2010, 49, 2626-2629.